Trial intelligence / Profile preview

Benralizumab in Moderate to Very Severe COPD (TERRANOVA)

NCT02155660Phase 3Completed

Sponsor
AstraZeneca
Start
Jun 2014
Primary completion
Apr 2018
Modality
Monoclonal Antibodies
Countries
26
01

Overview

A Phase 3 trial of benralizumab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Jun 2014; status: completed.

02

Drugs

benralizumab
03

Conditions

chronic obstructive pulmonary disease (COPD)

Beyond the preview

Go deeper on NCT02155660.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02155660.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call